Caris Life Sciences, Inc. (CAI) Stock Score, Valuation & Financial Research
Caris Life Sciences, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 34/100.
Quick answer for CAI
Caris Life Sciences, Inc. currently has a Wall Street Score of 34/100. The stored market price is $24.34. Its financial score is 34/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Caris Life Sciences, Inc. does
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
CAI financial snapshot
- Wall Street Score:
- 34/100
- Current price:
- $24.34
- Market capitalization:
- $6.88B
- Revenue:
- $989.6M
- Net income:
- $105.1M
- Free cash flow:
- $66.9M
- Cash:
- $690.9M
- Total debt:
- $452.4M
- EPS:
- 0.37
- P/E ratio:
- 65.4x
- Financial score:
- 34/100
- Valuation score:
- 0/100
- Revenue score:
- 44/100
What stands out
- Reported year-over-year revenue growth is +0.2%.
- Free cash flow is $66.9M, showing positive cash generation.
- The balance sheet shows $690.9M of cash versus $452.4M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 34/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research CAI
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.